JAK mutations in high-risk childhood acute lymphoblastic leukemia

Charles G. Mullighan(St. Jude Children's Research Hospital), Cheryl L. Willman(Mayo Clinic)

Proceedings of the National Academy of Sciences

May 22, 2009

10.1073/pnas.0811761106

Cited by 559

Related Papers

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

|Journal of Clinical Oncology|2003|2.7k

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

|Blood|2022|2.7k

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

|Blood|2000|1.6k

Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia

|New England Journal of Medicine|2009|1.4k

All-<i>trans</i>-Retinoic Acid in Acute Promyelocytic Leukemia

|New England Journal of Medicine|1997|1.1k